Investigational drug · Phase 2
EMB07
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Combination Therapy, Aggressive B-Cell Non-Hodgkin Lymphoma, EMB07.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "EMB07"
First trial start
2026
Apr 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EMB07", any sponsor or status.
Conditions studied
As listed on its trial records.
- Combination Therapy
- Aggressive B-Cell Non-Hodgkin Lymphoma
- EMB07
- phaseI/II
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "EMB07" as an intervention, largest first.
- First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory LymphomaStatus unknown
EpimAb Biotherapeutics (Suzhou)Co., Ltd.Industry
NCT05607498 · 150 participants (planned) · Start Mar 1, 2023 · Primary completion Oct 31, 2025
Drug: EMB07 · For: Advanced/Metastatic Solid Tumors; Relapse/Refractory Lymphoma
Sites: Frankston, Australia; Nedlands, Australia; Changsha, China · 10 sites in all
Shanghai EpimAb Biotherapeutics Co., Ltd.Industry
NCT07432022 · 115 participants (planned) · Start Apr 1, 2026 · Primary completion Jun 30, 2028
Drug: EMB07; Rituximab/Gemcitabine/Oxaliplatin · For: Combination Therapy; Aggressive B-Cell Non-Hodgkin Lymphoma; EMB07 and 1 more
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.